CORCEPT THERAPEUTICS INC (CORT)
US2183521028 - Common Stock
CORT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. CORT gets an excellent profitability rating and is at the same time showing great financial health properties. CORT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make CORT a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
CORT had positive earnings in the past year.
CORT had a positive operating cash flow in the past year.
In the past 5 years CORT has always been profitable.
CORT had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 17.08%, CORT belongs to the top of the industry, outperforming 96.94% of the companies in the same industry.
CORT has a Return On Equity of 20.95%. This is amongst the best in the industry. CORT outperforms 92.35% of its industry peers.
CORT has a Return On Invested Capital of 17.91%. This is amongst the best in the industry. CORT outperforms 95.41% of its industry peers.
CORT had an Average Return On Invested Capital over the past 3 years of 21.81%. This is significantly above the industry average of 16.40%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.08% | ||
| ROE | 20.95% | ||
| ROIC | 17.91% |
ROA(3y)20.33%
ROA(5y)20.48%
ROE(3y)23.7%
ROE(5y)23.34%
ROIC(3y)21.81%
ROIC(5y)22.46%
1.3 Margins
CORT has a Profit Margin of 22.01%. This is amongst the best in the industry. CORT outperforms 93.88% of its industry peers.
CORT's Profit Margin has declined in the last couple of years.
The Operating Margin of CORT (22.26%) is better than 89.80% of its industry peers.
CORT's Operating Margin has declined in the last couple of years.
The Gross Margin of CORT (98.66%) is better than 99.49% of its industry peers.
CORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.26% | ||
| PM (TTM) | 22.01% | ||
| GM | 98.66% |
OM growth 3Y-15.01%
OM growth 5Y-8.99%
PM growth 3Y-9.77%
PM growth 5Y-6.02%
GM growth 3Y0.08%
GM growth 5Y0.15%
2. Health
2.1 Basic Checks
CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, CORT has less shares outstanding
CORT has less shares outstanding than it did 5 years ago.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CORT has an Altman-Z score of 15.38. This indicates that CORT is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 15.38, CORT belongs to the top of the industry, outperforming 92.35% of the companies in the same industry.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.38 |
ROIC/WACC1.92
WACC9.31%
2.3 Liquidity
A Current Ratio of 4.39 indicates that CORT has no problem at all paying its short term obligations.
CORT has a Current ratio of 4.39. This is in the better half of the industry: CORT outperforms 60.71% of its industry peers.
A Quick Ratio of 4.31 indicates that CORT has no problem at all paying its short term obligations.
CORT's Quick ratio of 4.31 is fine compared to the rest of the industry. CORT outperforms 61.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.31 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 7.95% over the past year.
The Earnings Per Share has been growing slightly by 6.00% on average over the past years.
Looking at the last year, CORT shows a very strong growth in Revenue. The Revenue has grown by 20.03%.
The Revenue has been growing by 13.94% on average over the past years. This is quite good.
EPS 1Y (TTM)7.95%
EPS 3Y3.78%
EPS 5Y6%
EPS growth Q2Q100%
Revenue 1Y (TTM)20.03%
Revenue growth 3Y10.88%
Revenue growth 5Y13.94%
Revenue growth Q2Q31.33%
3.2 Future
CORT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.28% yearly.
The Revenue is expected to grow by 14.98% on average over the next years. This is quite good.
EPS Next Y17.03%
EPS Next 2Y21.61%
EPS Next 3Y29.87%
EPS Next 5Y28.28%
Revenue Next Year28.21%
Revenue Next 2Y18.23%
Revenue Next 3Y18.07%
Revenue Next 5Y14.98%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 24.21, CORT is valued on the expensive side.
83.16% of the companies in the same industry are more expensive than CORT, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 24.83. CORT is around the same levels.
Based on the Price/Forward Earnings ratio of 20.69, the valuation of CORT can be described as rather expensive.
Based on the Price/Forward Earnings ratio, CORT is valued cheaper than 81.12% of the companies in the same industry.
CORT is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.32, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.21 | ||
| Fwd PE | 20.69 |
4.2 Price Multiples
80.10% of the companies in the same industry are more expensive than CORT, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, CORT is valued cheaper than 83.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.76 | ||
| EV/EBITDA | 16.42 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The excellent profitability rating of CORT may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 29.87% in the coming years.
PEG (NY)1.42
PEG (5Y)4.04
EPS Next 2Y21.61%
EPS Next 3Y29.87%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CORCEPT THERAPEUTICS INC
NASDAQ:CORT (4/17/2024, 7:00:00 PM)
After market: 23 0 (0%)23
-0.39 (-1.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.38B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.21 | ||
| Fwd PE | 20.69 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.42
PEG (5Y)4.04
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.08% | ||
| ROE | 20.95% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 22.26% | ||
| PM (TTM) | 22.01% | ||
| GM | 98.66% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.39 | ||
| Quick Ratio | 4.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)7.95%
EPS 3Y3.78%
EPS 5Y
EPS growth Q2Q
EPS Next Y17.03%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)20.03%
Revenue growth 3Y10.88%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y